Tobin Schilke - 15 Dec 2021 Form 4 Insider Report for Revance Therapeutics, Inc.

Role: CFO
Signature: /s/ Terri McDowell, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 15 Dec 2021
Net transactions value: -$24,772
Form type: 4
Filing time: 17 Dec 2021, 16:31:04 UTC
Previous filing: 02 Jul 2021
Next filing: 04 Jan 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RVNC	Common Stock	Tax liability	$24,772	-1,556	-2.2%	$15.92	67,652	15 Dec 2021	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares withheld by and surrendered to the Issuer on December 15, 2021, to satisfy tax withholding obligations that arose in connection with the vesting of 4,500 shares of a Restricted Stock award ("RSA") for 18,000 shares. The RSA vests in four equal annual installments from December 15, 2018, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Inducement Plan) on each vesting date.

Content

Represents the number of shares withheld by and surrendered to the Issuer on December 15, 2021, to satisfy tax withholding obligations that arose in connection with the vesting of 4,500 shares of a Restricted Stock award ("RSA") for 18,000 shares. The RSA vests in four equal annual installments from December 15, 2018, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Inducement Plan) on each vesting date.